Oppenheimer Appoints James Yoo Managing Director in Healthcare Equity Capital Markets Investment Banking

Rhea-AI Summary

Oppenheimer (NYSE: OPY) announced on October 6, 2025 that James Yoo was named Managing Director in its Healthcare Equity Capital Markets Investment Banking Group.

The company states Mr. Yoo brings 27 years of industry experience and will focus on biotechnology equity capital markets, including PIPEs, follow-on offerings, CMPOs and registered direct transactions. According to the PR, Yoo previously served as Oppenheimer's Healthcare Specialist on the Sales & Trading desk since 2023 and held roles at Piper Sandler, Mizuho, and Nomura. Management comments in the release highlight Yoo's execution track record and biotech relationships as strengthening Oppenheimer's Healthcare ECM platform.

News Market Reaction

+0.24%

1 alert

+0.24% News Effect

On the day this news was published, OPY gained 0.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Seasoned industry professional brings 27 years of experience to expanding Healthcare platform

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today announced that James Yoo has been named a Managing Director within its Healthcare Equity Capital Markets Investment Banking Group. In this role, Mr. Yoo will focus on Biotechnology Equity Capital Markets transactions.

With 27 years of experience, Mr. Yoo has developed deep expertise in a range of financing structures, including Private Investment in Public Equity (PIPEs), Follow-on Offerings, Confidentially Marketed Public Offerings (CMPOs) and Registered Direct transactions.

"James brings an exceptional track record of execution and deep relationships across the biotechnology investment community to his new role," said Peter Bennett, Managing Director and Head of Equity Capital Markets Investment Banking at Oppenheimer. "His ability to navigate complex financing structures will further strengthen Oppenheimer's leadership in Healthcare Equity Capital Markets."

Before stepping into his new role, Mr. Yoo served as the Healthcare Specialist on Oppenheimer's Sales & Trading Desk since 2023, advising healthcare-dedicated investment funds and early- and late-stage biotechnology companies. Prior to Oppenheimer, he held various positions at leading firms such as Piper Sandler, Mizuho, and Nomura.

"I am honored to join Oppenheimer's Healthcare Equity Capital Markets Investment Banking Group at such an exciting time for the biotechnology sector," Yoo said. "The firm's collaborative culture and broad platform create an exceptional environment to deliver innovative capital markets solutions. I look forward to working with my colleagues to help biotech companies access the financing they need to advance groundbreaking science and improve patient outcomes."

About Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary, and related entities, provides a full range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions. For more information, please visit www.oppenheimer.com.

Media Contact:
Joseph Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
jkuo@haventower.com or mdugan@haventower.com

View original content:https://www.prnewswire.com/news-releases/oppenheimer-appoints-james-yoo-managing-director-in-healthcare-equity-capital-markets-investment-banking-302574286.html

SOURCE Oppenheimer & Co. Inc.

FAQ

Who is James Yoo and what role did Oppenheimer (OPY) announce on October 6, 2025?

According to the PR, James Yoo was named Managing Director in Healthcare Equity Capital Markets, focused on biotechnology transactions.

What experience does James Yoo bring to Oppenheimer's Healthcare ECM team?

The PR states Yoo has 27 years of experience and expertise in PIPEs, follow-on offerings, CMPOs, and registered direct transactions.

How long has James Yoo been at Oppenheimer before this promotion (OPY)?

Per the release, Yoo served as Oppenheimer's Healthcare Specialist on the Sales & Trading desk since 2023.

Will James Yoo's appointment at Oppenheimer (OPY) change the firm's biotech coverage focus?

The PR indicates Yoo will strengthen the firm's Healthcare Equity Capital Markets focus on biotechnology financings; no specific coverage changes or metrics were disclosed.

Does the press release state any financial targets or transactions tied to James Yoo's hiring at OPY?

No. The PR highlights Yoo's background and role but does not disclose financial targets, deal values, or guidance.

Where can investors find more information about Oppenheimer's Healthcare Equity Capital Markets team and leadership changes?

The company suggests checking Oppenheimer's investor relations or press release page for official updates and biographies.